Corcept Therapeutics (FRA:HTD) Intangible Assets: €0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:HTD Corcept Therapeutics Inc FRA:HTD
86 GF Score
Price €74.56
GF Value €52.23
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Corcept Therapeutics Intangible Assets?

Corcept Therapeutics FRA:HTD -0.32% 86 Intangible Assets is €0.0 Mil as of Mar. 2026. GuruFocus rates FRA:HTD with a GF Score™ of 86/100 and a GF Value™ of €52.23 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Corcept Therapeutics's intangible assets for the quarter that ended in Mar. 2026 was €0.0 Mil.


Corcept Therapeutics  (FRA:HTD) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Corcept Therapeutics Intangible Assets Related Terms


Corcept Therapeutics Intangible Assets Historical Data

* Premium members only.

The historical data trend for Corcept Therapeutics's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics Intangible Assets Chart

Corcept Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Intangible Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Corcept Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:HTD
86GF Score
Corcept Therapeutics Inc FRA:HTD
Intangible Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corcept Therapeutics Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.

Frequently Asked Questions Learn more about Intangible Assets →
What does a Intangible Assets of €0.0 Mil mean?
Corcept Therapeutics (FRA:HTD) has a Intangible Assets of €0.0 Mil as of Mar. 2026. Intangible assets include patents, goodwill and trade secrets. View historical data on Corcept Therapeutics and its competitors.
Is Corcept Therapeutics' Intangible Assets too high?
Corcept Therapeutics' current Intangible Assets is €0.0 Mil. Overall, Corcept Therapeutics has a GF Score™ of 86/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Intangible Assets compare to PRAX and IBRX?
Corcept Therapeutics' Intangible Assets of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intangible Assets for a Biotechnology company?
A good Intangible Assets depends on the Biotechnology industry context. However, Intangible Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intangible Assets mean?
A high Intangible Assets can signal that a stock is expensive relative to its fundamentals. Intangible assets include patents, goodwill and trade secrets. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current Intangible Assets is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (FRA:HTD) is currently considered Significantly Overvalued. The stock's GF Value™ is €52.23, compared to a current price of €74.56 — trading 42.8% above its estimated fair value. The current Intangible Assets is €0.0 Mil. Corcept Therapeutics' overall GF Score™ is 86/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intangible Assets calculated?
Intangible Assets is calculated from a company's financial statements. For Corcept Therapeutics (FRA:HTD), the current Intangible Assets is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corcept Therapeutics (FRA:HTD) Overvalued in 2026?

Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued. The current stock price of €74.56 is trading 42.8% above its estimated GF Value™ of €52.23. GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:HTD:

  • Intangible Assets: €0.0 Mil
  • GF Value™: €52.23 vs. price of €74.56 (42.8% above fair value)
  • GF Score™: 86/100 with 8 warning signs

No single metric tells the full story. See the FRA:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Corcept Therapeutics Business Description

Other Exchanges CORT:USA1CORT:Italy0I3Q:UK
Address 101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
86GF Score

Get the complete analysis for FRA:HTD

Intangible Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€74.56
Price
€52.23
GF Value